Everything below concerns AOD-9604. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-04-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
== Anticoagulant effect == A. sinensis may increase the anticoagulant effects of the drug warfarin (as it contains coumarins), and consequently may increase the risk of bleeding. Caution is needed when consumed with herbs (such as ginkgo or garlic), which may affect blood clotting.
This formula was developed by Levey et al. The 2009 CKD-EPI formula was suggested to improve cardiovascular risk prediction over the MDRD Study formula in a middle-age population. The 2021 CKD-EPI formula does not include a race coefficient (see discussion below). The 2021 CKD-EPI equation is:
=== Casting === Upon the pilot order announcement, Bates was cast to star. Skye P. Marshall, Jason Ritter, David Del Rio, and Leah Lewis joined the main cast upon the series order announcement. On February 8, 2024, Beau Bridges was cast in a recurring capacity. On April 1, 2024, Yael Grobglas joined the cast in a recurring role. In August 2024, Andrea Londo and Piper Curda were cast in recurring capacities. On September 8, 2024, Bates said that Matlock was to be her final role before retirement. On October 9, 2024, she walked it back, saying that "I think that they got a bit confused." On August 1, 2025, Justina Machado joined the cast in a recurring role for the second season. On October 9, 2025, it was reported that Del Rio had been fired due to a sexual assault allegation involving Lewis. On December 11, 2025, Henry Haber and Sarah Wright Olsen were cast in recurring capacities for the second season.
Tanabe Young Investigator Award from the American College of Clinical Pharmacology (2014) Division for Drug Metabolism Early Career Achievement Award by the American Society for Pharmacology and Experimental Therapeutics (ASPET) (2015) The International Society for the Study of Xenobiotics (ISSX) North American New Investigator Award in Honor of James R. Gillette (2017) The Daily Record Leading Women Award (2017) Leon I. Goldberg Young Investigator Award from the American Society for Clinical Pharmacology and Therapeutics (2017) John J. Abel Award in Pharmacology from ASPET (2019)
Sources: en.wikipedia.org
Other polonium compounds include the polonite, potassium polonite; various polonate solutions; and the acetate, bromate, carbonate, citrate, chromate, cyanide, formate, (II) or (IV) hydroxide, nitrate, selenate, selenite, monosulfide, sulfate, disulfate or sulfite salts. A limited organopolonium chemistry is known, mostly restricted to dialkyl and diaryl polonides (R2Po), triarylpolonium halides (Ar3PoX), and diarylpolonium dihalides (Ar2PoX2). Polonium also forms soluble compounds with some ligands, such as 2,3-butanediol and thiourea.
== PCT and amphetamines == Excessive overdose on amphetamine or its analogs can induce systemic inflammation; in a case report of amphetamine overdose, without bacterial infection, significant elevations in procalcitonin were observed.
== Advisory roles and international engagement == Singh represented India on numerous national and international forestry bodies. He served as Chairman of the IX Commonwealth Forestry Conference in January 1968, where delegates recognized his effective moderation in revitalizing the conference's focus on global wood trends and economic forestry. His other international leadership roles included serving as Chairman of the Food and Agriculture Organization (FAO) Committee on Range Forest Management, Chairman of the Teak Sub-Commission, Chairman of the Technical Committee on Forestry and Forest Products (1965), and Vice-Chairman of the FAO Committee on Forest Development in the Tropics. He also participated in the Sixth World Forestry Congress in 1966. In 1970, following his retirement, the Government of India appointed him to the National Commission on Agriculture. Contributing heavily to the commission's 1976 report (Part IX on Forestry), Singh advocated for integrating forest management with agricultural objectives, emphasizing long-term ecological sustainability over the politically driven expansion of arable land.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.